The selective BH3-mimetic agent ABT-199 targeting BCL2 increases the sensitivity to AICAR in BCL2-overexpressing MCL cells [159,225] (Table 3, Figure 3). The gene discussed is BCL2; the disease is mantle cell lymphoma.